Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Level 4 - case-series / case-control
Pediatric case series without controls
PubMed 34302703 · doi:10.1002/pbc.29261
What was done
Descriptive case series detailing the clinical presentation, management, and treatment responses of two pediatric patients with the TAFRO clinical subtype of idiopathic multicentric Castleman disease (iMCD-TAFRO).
What was found
One patient responded to IL-6 blockade. The second patient failed siltuximab and chemotherapy but responded to JAK inhibition with ruxolitinib. The abstract reports no numerical outcome values or laboratory figures.
Why it matters
It provides the first reported evidence of successful JAK inhibition (ruxolitinib) in a pediatric patient with treatment-refractory iMCD-TAFRO.
Limits
Extremely small sample size (n = 2), retrospective and uncontrolled design, lack of quantitative data in the abstract, and potential for publication bias inherent to case reports.
Cited by
- supports A refractory Castleman disease patient in Chicago who failed sirolimus responded successfully to ruxolitinib.